Drug intelligence / Profile preview

matsupexole

Development stage: Phase 2
Lead developer: Kissei Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**Matsupexole** is a **small molecule** non-ergot **dopamine D2 receptor agonist** developed primarily for **Parkinson's disease**. It belongs to the class of octahydrothienoquinoline derivatives (molecular formula C22H34N6O2S) and acts by stimulating dopamine D2 receptors to alleviate motor symptoms. Originating from **Kissei Pharmaceutical**, it has been licensed to **AffaMed Therapeutics** for development in regions like China, with phase II trials completed in Japan (NCT04867551) and ongoing late phase II trials as of 2024-2025.

Other names: matsupexolum

Targets

DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)

Beyond the preview

Go deeper on matsupexole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on matsupexole.

Explore the full profile